about
Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human gliomaLow levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study.Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV.Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery.Human cytomegalovirus particles directly suppress CD4 T-lymphocyte activation and proliferation.Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.Increased survival using delayed gamma knife radiosurgery for recurrent high-grade glioma: a feasibility study.Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Optimized protein extraction from cryopreserved brain tissue samples.Neuronavigation for arteriovenous malformation surgery by intraoperative three-dimensional ultrasound angiography.Valganciclovir in patients with glioblastoma.Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir.[Questionable debate on antiviral therapy in malignant glioblastoma].Proliferation, migration and differentiation of ependymal region neural progenitor cells in the brainstem after hypoglossal nerve avulsion
P50
Q33869598-F6BCE19A-B4DB-4973-86AE-237206D07E2CQ34198365-83C1CA72-F473-4EE3-9951-88BB96528DBCQ35506920-5140A125-D0A7-4FE9-A39A-3B30CCDDD5BDQ36060293-DF0EF991-CA7A-46FC-B9D5-5118830936CBQ39189976-666BFD8E-3319-4573-8452-AB5087C654A6Q39279856-058B8264-0876-486A-98AC-1786FA754DD2Q39468197-0D00814E-F3B7-4F07-AA08-49B6C9F7A840Q40869992-88FDE61D-F418-4B70-A2AC-7EA856485650Q44999375-6D956D0C-7F8A-4C63-AE10-7FA81AA7F18AQ45327856-63E5203D-B56A-4C7C-B584-C1FF7E762926Q47153393-8FE5226D-8BE8-4D5D-B040-A1F338284433Q48200393-CE3939B2-9969-43D9-A9C3-0419F0FD3605Q48213513-260A5E5B-84D0-4561-B03E-177FF49D6C47Q48859400-FC29A47A-9A40-4B48-B658-455C79AA7989Q51855905-FAD0C0DB-6FE1-433A-8210-563127CDA7D1Q55460766-A6ABC6C8-154C-42D7-8DA0-A8119E7716C4Q83447894-E75ECF44-FEC7-4042-B76E-1D4C6562C25A
P50
name
Inti Peredo
@en
type
label
Inti Peredo
@en
prefLabel
Inti Peredo
@en